This article highlights ten leading cell therapy companies, all of which have promising cell therapy products being evaluated in clinical trials. These 10 companies were chosen, because they are market leaders, with robust financial funding, novel technologies, and strong therapeutic pipelines.
These leading cell therapy companies include:
- Mesoblast Ltd.
- Asterias Biotherapeutics
- TiGenix NV
- Cynata Therapeutics
- Cytori Therapeutics
- Astellas Pharma, and Subsidiary Ocata Therapeutics
- Gamida Cell Ltd.
- Pluristem Therapeutics
As shown in the table below below, allogeneic cell therapy manufacturing is much more common among leading cell therapy companies. Among the ten leading cell therapy companies analyzed below, eight focus exclusively on allogeneic cell therapy product development, one develops both autologous and allogeneic cell therapies products, and one is developing autologous cell therapies.
While these companies do not represent all cell therapy companies, the breakdown of autologous versus allogeneic cell therapy development among these market leaders is important to consider and reflective of broader trends across the cell therapy marketplace.
Clearly, there are opportunities for developing and manufacturing both autologous and allogeneic cell therapy products, which vary greatly in their manufacturing requirements, routes for patient administration, and cost structures. Clinical data in support of patient-specific therapy has been highly compelling.
Nonetheless, analysis of cell therapy market leaders clearly reveals that allogeneic product development is dominating over autologous product development on a global basis.